中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

22 records (took 0.014 seconds)

    HYDROGEL BIOSCAFFOLDINGS AND BIOMEDICAL DEVICE COATINGS
    1.
    发明申请
    HYDROGEL BIOSCAFFOLDINGS AND BIOMEDICAL DEVICE COATINGS 审中-公开

    公开(公告)号：WO2006113407A3

    公开(公告)日：2006-10-26

    申请号：PCT/US2006/014021

    申请日：2006-04-13

    Applicant: ADVANCED CARDIOVASCULAR SYSTEMS, INC. ,  CLAUDE, Charles ,  KWOK, Connie ,  MICHAL, Gene ,  QU, Jihong ,  LIAO, Sophia

    Inventor： CLAUDE, Charles ,  KWOK, Connie ,  MICHAL, Gene ,  QU, Jihong ,  LIAO, Sophia

    IPC: A61L27/52 ,  A61L27/20 ,  A61L31/10 ,  A61L31/14 ,  A61K9/00

    Abstract: Bioscaffoldings formed of hydrogels that are crosslinked in situ in an infarcted region of the heart (myocardium) by a Michael's addition reaction or by a disulfide bond formed by an oxidative process are described. Each of the bioscaffoldings described includes hyaluronan as one of the hydrogel components and the other component is selected from collagen, collagen-laminin, poly-1- lysine, and fibrin. The bioscaffolding may further include an alginate component. The bioscaffoldings may have biofunctional groups such as angiogenic factors and stem cell homing factors bound to the collagen, collagen-laminin, poly-1- lysine, or fibrinogen hydrogel component. In particular, the biofunctional groups may be PRl 1, PR39, VEGF, bFGF, a polyarginine/DNA plasmid complex, or a DNA/polyethyleneimine (PEI) complex. Additionally, the hydrogel components may be injected into the infarct region along with stem cells and microspheres containing stem cell homing factors. The bioscaffolding may be formed on a stent or a cardiac medical device.

    HYDROGEL BIOSCAFFOLDINGS AND BIOMEDICAL DEVICE COATINGS
    2.
    发明申请
    HYDROGEL BIOSCAFFOLDINGS AND BIOMEDICAL DEVICE COATINGS 审中-公开
    HYDROGEL生物医药和生物医疗器械涂料

    公开(公告)号：WO2006113407A2

    公开(公告)日：2006-10-26

    申请号：PCT/US2006014021

    申请日：2006-04-13

    Applicant: ADVANCED CARDIOVASCULAR SYSTEM ,  CLAUDE CHARLES ,  KWOK CONNIE ,  MICHAL GENE ,  QU JIHONG ,  LIAO SOPHIA

    Inventor： CLAUDE CHARLES ,  KWOK CONNIE ,  MICHAL GENE ,  QU JIHONG ,  LIAO SOPHIA

    CPC classification number: A61L27/3834 ,  A61L27/26 ,  A61L27/3826 ,  A61L27/383 ,  A61L27/3873 ,  A61L27/52 ,  C08L89/06 ,  C08L5/08

    Abstract: Bioscaffoldings formed of hydrogels that are crosslinked in situ in an infarcted region of the heart (myocardium) by a Michael's addition reaction or by a disulfide bond formed by an oxidative process are described. Each of the bioscaffoldings described includes hyaluronan as one of the hydrogel components and the other component is selected from collagen, collagen-laminin, poly-1- lysine, and fibrin. The bioscaffolding may further include an alginate component. The bioscaffoldings may have biofunctional groups such as angiogenic factors and stem cell homing factors bound to the collagen, collagen-laminin, poly-1- lysine, or fibrinogen hydrogel component. In particular, the biofunctional groups may be PRl 1, PR39, VEGF, bFGF, a polyarginine/DNA plasmid complex, or a DNA/polyethyleneimine (PEI) complex. Additionally, the hydrogel components may be injected into the infarct region along with stem cells and microspheres containing stem cell homing factors. The bioscaffolding may be formed on a stent or a cardiac medical device.

    Abstract translation: 描述了由水凝胶形成的生物支架，其通过迈克尔加成反应或通过氧化过程形成的二硫键在心脏（心肌）的梗死区域原位交联。 所描述的每个生物支架包括透明质酸作为水凝胶组分之一，另一组分选自胶原，胶原 - 层粘连蛋白，聚-1-赖氨酸和纤维蛋白。 生物支架还可包括藻酸盐组分。 生物支架可以具有生物功能组，例如血管生成因子和与胶原，胶原 - 层粘连蛋白，聚-1-赖氨酸或纤维蛋白原水凝胶组分结合的干细胞归巢因子。 特别地，生物功能基团可以是PR11，PR39，VEGF，bFGF，聚精氨酸/ DNA质粒复合物或DNA /聚乙烯亚胺（PEI）复合物。 此外，水凝胶组分可以与含有干细胞归巢因子的干细胞和微球一起注射到梗死区域中。 生物支架可以形成在支架或心脏医疗装置上。

    TREATMENT OF AUTOIMMUNE DISEASE
    10.
    发明申请
    TREATMENT OF AUTOIMMUNE DISEASE 审中-公开
    治疗自发性疾病

    公开(公告)号：WO1995007096A1

    公开(公告)日：1995-03-16

    申请号：PCT/AU1994000522

    申请日：1994-09-02

    Applicant: LA TROBE UNIVERSITY ,  BERNARD, Claude, Charles, Andre ,  KERLERO DE ROSBO, Nicole, Claude, Marie

    Inventor： LA TROBE UNIVERSITY

    IPC: A61K38/17

    CPC classification number: C07K14/4713 ,  A61K38/00 ,  C07K16/4241

    Abstract: The present invention provides methods of, and pharmaceutically-acceptable/veterinary-acceptable compositions suitable for, treating the T-cell and/or B-cell mediated autoimmune disease, multiple sclerosis, in human beings and the lower animals, respectively, by the administration to them of: (i) myelin oligodendrocyte glycoprotein (MOG); or (ii) a MOG-like protein; or (iii) an immunodominant region of MOG or MOG-like protein, in particular, an immunodominant epitope of MOG or MOG-like protein; or (iv) an anti-idiotypic antibody to a protein or peptide of (i) to (iii); or (v) monoclonal anti-idiotypic antibodies to a protein or peptide of (i) to (iii). The present invention further provides diagnostic agents, methods and kits for detecting multiple sclerosis or other T-cell and/or B-cell mediated autoimmune diseases in humans or lower animals. The present invention still further provides nucleotide sequences that code for human MOG or human MOG-like protein or an immunodominant region of human MOG or an immunodominant epitope of human MOG, as well as embracing human MOG or human MOG-like protein or an immunodominant region of human MOG or an immunodominant epitope of human MOG, obtained by standard procedures for protein synthesis or by recombinant DNA techniques.

    Abstract translation: 本发明提供了适用于通过给药，分别治疗人和低等动物的T细胞和/或B细胞介导的自身免疫性疾病，多发性硬化的方法和药学上可接受/兽医学可接受的组合物 对他们：（i）髓鞘少突胶质细胞糖蛋白（MOG）; 或（ii）MOG样蛋白; 或（iii）MOG或MOG样蛋白的免疫显性区，特别是MOG或MOG样蛋白的免疫优势表位; 或（iv）对（i）至（iii）的蛋白质或肽的抗独特型抗体; 或（v）针对（i）至（iii）的蛋白质或肽的单克隆抗独特型抗体。 本发明还提供用于检测人类或低等动物中多发性硬化或其它T细胞和/或B细胞介导的自身免疫性疾病的诊断剂，方法和试剂盒。 本发明还提供编码人MOG或人MOG样蛋白或人MOG免疫显性区或人MOG免疫显性表位的核苷酸序列，以及包含人MOG或人MOG样蛋白或免疫显性区 的人MOG或人MOG的免疫显性表位，通过蛋白质合成的标准方法或通过重组DNA技术获得。

Patent Agency Ranking